110 related articles for article (PubMed ID: 31530784)
1. [A Case of Anaphylactic Shock after First Administration of Oxaliplatin].
Shiota T; Okamura R; Nakayama H; Kato T; Kito Y; Sata R
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1433-1435. PubMed ID: 31530784
[TBL] [Abstract][Full Text] [Related]
2. [Anaphylactic reaction to oxaliplatin--a case of colon cancer].
Sagawa T; Sato Y; Abe S; Okuda T; Araki N; Takahari D; Okamoto T; Takayama T; Kato J; Niitsu Y
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2093-6. PubMed ID: 17197761
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Colorectal Cancer with Anaphylactic Shock to Oxaliplatin].
Machida T; Tanaka J; Terashima T
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2154-6. PubMed ID: 26805295
[TBL] [Abstract][Full Text] [Related]
4. Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer.
Gao SR; Li LM; Xia HP; Wang GM; Xu HY; Wang AR
Asian Pac J Cancer Prev; 2015; 16(9):4037-40. PubMed ID: 25987082
[TBL] [Abstract][Full Text] [Related]
5. [A case of cardiopulmonary arrest due to hypersensitivity reaction to oxaliplatin for multiple liver and lung metastases of colon cancer].
Tamura H; Kameyama H; Toge K; Usui K; Enomoto T; Watanabe N; Hayashi T; Shimada Y; Wakai T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1844-5. PubMed ID: 25731349
[TBL] [Abstract][Full Text] [Related]
6. A case of idiosyncratic liver injury after oxaliplatin-induced thrombocytopenia.
Honda S; Tsujimoto M; Minegaki T; Mori T; Muraoka J; Nishiguchi K
J Clin Pharm Ther; 2020 Apr; 45(2):373-375. PubMed ID: 31671217
[TBL] [Abstract][Full Text] [Related]
7. Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin.
Rosique-Robles D; Vicent Verge JM; Borrás-Blasco J; Giner-Marco V; Casterá E; Galan-Brotons A; Abad J
Int J Clin Pharmacol Ther; 2007 Nov; 45(11):606-10. PubMed ID: 18077926
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Rectal Cancer with Lymphangiosis Carcinomatosa Successfully Treated with Chemotherapy Despite Anaphylactic Reaction to Oxaliplatin].
Ozaki K; Hayashida R; Nishi T; Ishibashi Y; Sakurai K; Nishimura Y; Akagi Y
Gan To Kagaku Ryoho; 2015 Dec; 42(13):2481-3. PubMed ID: 26809309
[TBL] [Abstract][Full Text] [Related]
9. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445
[TBL] [Abstract][Full Text] [Related]
10. A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
Saridaki Z; Bozionelou V; Kentepozidis N; Kotsakis A; Vardakis N; Kalykaki A; Gioulbasanis I; Karampeazis A; Vamvakas L; Georgoulias V; Mavroudis D
Oncology; 2007; 72(1-2):45-50. PubMed ID: 17998790
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
Wein A; Riedel C; Brückl W; Merkel S; Ott R; Hanke B; Baum U; Fuchs F; Günther K; Reck T; Papadopoulos T; Hahn EG; Hohenberger W
Oncology; 2003; 64(2):131-8. PubMed ID: 12566910
[TBL] [Abstract][Full Text] [Related]
12. [FOLFOX4 regimen versus DP(O)F regimen for advanced gastric cancer].
Wu F; Zhang HG; Ran FW; Zhang XR; Shi YK
Ai Zheng; 2008 Apr; 27(4):413-7. PubMed ID: 18423129
[TBL] [Abstract][Full Text] [Related]
13. Delayed hypersensitivity to oxaliplatin in a nigerian patient with colorectal cancer-A case report.
Aliyu UM; Okwonna CO
J Oncol Pharm Pract; 2021 Jul; 27(5):1258-1260. PubMed ID: 33131450
[TBL] [Abstract][Full Text] [Related]
14. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
Maindrault-Goebel F; André T; Tournigand C; Louvet C; Perez-Staub N; Zeghib N; De Gramont A
Eur J Cancer; 2005 Oct; 41(15):2262-7. PubMed ID: 16154353
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer.
Lan YQ; Wu RP; Huang XB; Wang XL; Zhong DT; Huang CY; Song JT
Tumori; 2018; 104(1):22-29. PubMed ID: 28777427
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Dai X; Zhang X; Wang C; Jiang J; Wu C
Oncotarget; 2017 May; 8(18):30495-30501. PubMed ID: 27911869
[TBL] [Abstract][Full Text] [Related]
17. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Stickel F; Jüngert B; Brueckl V; Schirner I; Brueckl WM; Männlein G; Hegewald J; Mühldorfer S; Bittorf B; Hohenberger W; Hahn EG; Wein A
Anticancer Drugs; 2003 Oct; 14(9):745-9. PubMed ID: 14551509
[TBL] [Abstract][Full Text] [Related]
18. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
19. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Nozawa H; Muto Y; Yamada Y
Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
[TBL] [Abstract][Full Text] [Related]
20. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
